BASKING RIDGE, N.J., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS), a company combining a leading cell therapy service provider with a development pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and ischemic repair, announces today that the Company's management will present at multiple conferences in September and early October.
7th Annual Symposium on Translational Circulatory and Stem Cell Research
- Date and Time: Friday, September 11, 2015, 8:30 AM TW
- Venue: Sapphire Hall, Kaohsiung Chang Gung Memorial Hospital
- Presenter: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: The Microvasculature as a Therapeutic Target in Ischemic Tissue Repair
2nd Annual Global Summit on Melanoma
- Date and Time: Saturday, September 19, 2015, 11:55 AM PT
- Venue: The Langham Hotel, Pasadena, California
- Presenter: Dr. Robert Dillman, Vice President, Oncology
- Topic: CLBS20: Autologous Dendritic Cell-Tumor Initiating Cells
ISCT Europe 2015 Regional Meeting
- Venue: Barcelo Sevilla Renacimiento, Seville, Spain
- Website: http://www.isct-eu2015.com/
Session 1
- Date and Time: Thursday, September 24, 2015,11:00 AM CET
- Session Chair: Dr. Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
- Topic: How to Drive the Translation of Cellular Therapies for the Benefit of Patients: Challenges and Critical Success Factors
Session 2
- Date and Time: Thursday, September 24, 2015, 3:15 PM CET
- Session Chair: Dr. Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
- Topic: On Dose Finding, Frequency and Route of Administration, What is the Cell Therapy Equivalent to PK/PD Studies?
NHLBI Symposium on Cardiovascular Regenerative Medicine
- Date and Time: Monday, September 29, 2015, 7:30 AM ET
- Venue: National Heart, Lung, and Blood Institute, Bethesda, Maryland
- Website: https://www.nhlbi.nih.gov/news/events/symposium-cardiovascular-regenerative-medicine
- Poster Presenter: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: CD34 Cell Therapy for Ischemic Repair: A Randomized, Double-Blind, Placebo Controlled Clinical Trial of Intracoronary Infusion of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI (PreSERVE-AMI)
Cell Therapy Bioprocessing & Commercialization
- Venue: Hilton Alexandria Mark Center, Alexandria, Virginia
- Website: http://www.ibclifesciences.com/CellTherapy/overview.xml
Session 1
- Date and Time: Tuesday, September 30, 2015, 4:00 PM ET
- Presenter: Dr. Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President, PCT
- Topic: Partnering with a CMO Along the Road to Commercial Cell Therapy Manufacturing
Session 2
- Date and Time: Thursday, October 1, 2015, 8:45 AM ET
- Moderator: Dr. Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
- Panelist: Dr. Ann Daus, Vice President, Quality Assurance and Quality Control, PCT
- Topic: Alignment with Commercialization
Session 3
- Date and Time: Thursday, October 1, 2015, 11:00 AM ET
- Presenter: Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT
- Topic: What Can Automation Do for You and When – Strategic Considerations, Examples and Lessons Learned
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.